Mucosal immunisation for enteric diseases: Current practice and future prospects

BioDrugs

Volumn 7, Issue 2, 1997, Pages 134-157

  Sabbaj, Steffanie ^a,c   Kiyono, Hiroshi ^a,b   McGhee, Jerry R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CHOLERA VACCINE; CYTOKINE; HEPATITIS A VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; SALMONELLOSIS VACCINE; SHIGELLA VACCINE; VIRUS VACCINE;

DRUG DELIVERY SYSTEM; ENTERITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; PEYER PATCH; PRIORITY JOURNAL; REVIEW;

EID: 0030762397     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707020-00006     Document Type: Review

References (151)

1. Mestecky J. The common mucosal immune system and current strategies tor induction of immune responses in external secretions. J Clin Immunol 1987; 7: 265-76
2. McGhee JR, Kiyono H. New perspectives in vaccine development: mucosal immunity to infections. Infect Agent Dis 1993; 2: 55-73
3. Owen RL, Jones AL. Epithelial cell specialization within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles. Gastroenterology 1974; 66: 189-203
4. Wolf JL, Rubin DH, Finberg R, et al. Intestinal M cells: a pathway for entry of reovirus into the host. Science 1981; 212: 471-2
5. Kiyono H, McGhee JR. T helper cells for mucosal immune responses. In: Ogra PL, Mestecky J, Lamm ME, et al., editors. Handbook of mucosal immunology. San Diego: Academic Press, 1994: 263-74
6. Butcher EC, Rouse RV, Coffman RL, et al. Surface phenotype of Peyer's patch germinal center cells: implications for the role of germinal centers in B cell differentiation. J Immunol 1982; 129: 2698-707
7. Isakson PC, Puré E, Vitetta ES, et al. T cell-derived B cell differentiation factor(s): effect on the isotype switch of murine B cells. J Exp Med 1982; 155: 734-48
8. Coffman RL, Lehman DA, Shrader B. Transforming growth factor β specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med 1989; 170: 1039-44
9. Sonoda E, Matsumoto R, Hitoshi Y, et al. Transforming growth factor β induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med 1989; 170: 1415-20
10. 1 selectively stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J Exp Med 1993; 177: 1031-7
11. McIntyre TM, Kehry MR, Snapper CM. Novel in vitro model for high-rate IgA class switching. J Immunol 1995; 154: 3156-61
12. Coffman RL, Shrader B, Carty J, et al. A mouse T cell product that preferentially enhances IgA production. I. Biological characterization. J Immunol 1987; 139: 3685-90
13. Harriman GR, Kunimoto DY, Elliot JF, et al. The role of IL-5 in IgA B cell differentiation. J Immunol 1988; 140: 3033-9
14. Beagley KW, Eldridge JH, Kiyono H, et al. Recombinant murine IL-5 induces high-rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J Immunol 1988; 141: 2035-42
15. Murray PD, McKenzie DT, Swain SL, et al. Interleukin 5 and interleukin 4 produced by Peyer's patch T cells selectively enhance immunoglobulin A expression. J Immunol 1987; 139: 2669-74
16. Lehman DA, Coffman RL. The effects of IL-4 and IL-5 on the IgA response by murine Peyer's patch B cell subpopulations. J Immunol 1988; 141: 2050-6
17. Beagley KW, Eldridge JH, Lee F, et al. Interleukins and IgA synthesis: human and murine interleukin 6 induce high-rate IgA secretion in IgA-committed B cells. J Exp Med 1989; 169: 2133-48
18. Fujihashi K, McGhee JR, Lue C, et al. Human appendix B cells naturally express receptors for and respond to interleukin 6 with selective IgA1 and IgA2 synthesis. J Clin Invest 1991; 88: 248-52
19. Defrance T, Vanbervliet B, Brière F, et al. Interleukin 10 and transforming growth factor β cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992; 175: 671-82
20. McGhee JR, Mestecky J, Dertzbaugh MT, et al. The mucosul immune system: from fundamental concepts to vaccine development. Vaccine 1992; 10: 75-88
21. Mega J, Bruce MG, Beagley KW, et al. Regulation of mucosal responses by CD4+ T lymphocytes: effects of anti-L3T4 treatment on the gastrointestinal immune system. Int Immunol 1991; 3: 793-805
22. Ramsay AJ, Husband AJ, Ramshaw IA, et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994; 264: 561-3
23. Mossman TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-73
24. Scott P, Natovitz P, Coffman RL, et al. Immunoregulation for cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different Th subsets and respond to distinct parasite antigens. J Exp Med 1988; 168: 1675-84
25. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990: 8: 303-33
26. Taguchi T, McGhee JR, Coffman RL, et al. Analysis of Th1 and Th2 cells in murine gut-associated tissues: frequencies of CD4+ and CD8+ T cells that secrete IFN-γ and IL-5. J Immunol 1990; 145: 68-77
27. Mega J, McGhee JR, Kiyono H. Cytokine- and Ig-producing cells in mucosal effector tissues: analysis of IL-5 and IFN-γ producing T cells. T cell receptor expression and IgA plasma cells from mouse salivary gland-associated tissues. J Immunol 1992; 148: 2030-9
28. Hiroi T, Fujihashi K, McGhee JR, et al. Characterisation of cytokine-producing cells in mucosal effector sites. CD3+ T cells of Th1 and Th2 type in salivary gland-associated tissues. Eur J Immunol 1994; 24: 2653-8
29. Xu-Amano J, Aicher WK, Taguchi T, et al. Selective induction of Th2 cells in murine Peyer's patches by oral immunisation. Int Immunol 1992; 4: 433-45
30. Ramarathinam L, Shaban RA, Niesel DW, et al. Interferon gamma (INF-γ) production by gut-associated lymphoid tissue and spleen following oral Salmonella typhimurium challenge. Microb Pathog 1991; 11: 347-56
31. Muotiala A, Mäkela PH. The role of IFN-γ in murine Salmonella typhimurium infection. Microb Pathog 1990; 8: 135-41
32. Nauciel C, Espinasse-Maes F. Role of gamma interferon and tumor necrosis factor alpha in resistance to Salmonella typhimurium infection. Infect Immun 1992; 60: 450-4
33. Vancott JL, Staats HF, Pascual DW, et al. Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages and derived cytokines following oral immunization with live recombinant Salmonella. J Immunol 1996; 156: 1504-14
34. Jackson RJ, Fujihashi K, Xu-Amano J, et al. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 1993; 61: 4272-9
35. Sztein MB, Wasserman SS, Tacket CO, et al. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis 1994; 170: 1508-17
36. Couvreur P, Puisieux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Deliv Rev 1993; 10: 141-62
37. Eldridge JH, Hammond CJ, Meulbroek JA, et al. Controlled vaccine release in the gut associated lymphoid tissue. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release 1990; 11: 205-14
38. Mowat AMcI, Donachie AM, Reid G, et al. Immune-stimulating complexes containing Quil A and protein antigen prime class IMHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991; 72: 317-22
39. Mowal AMcI, Maloy KJ, Donachie AM. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 1993; 80: 527-34
40. O'Hagan DT, Mcgee JP, Holmgren J, et al. Biodegradable microparticles for oral immunization. Vaccine 1993; 11: 149-54
41. Fujii Y, Aramaki Y, Hara T, et al. Enhancement of systemic and mucosul immune responses following oral administration of liposomes. Immunology Lett 1993; 36: 65-70
42. Faden H, Modlin JF, Thoms ML, et al. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990; 162: 1291-7
43. Ogra PL. Mucosal immune response to poliovirus vaccines in childhood. Rev Infect Dis 1984; 6 Suppl. 2: 361-8
44. Simon J, Kutubuddin M, Chow M. Characterization of poliovirus-specific T lymphocytes in the peripheral blood of Sabinvaccinated humans. J Virol 1993; 67: 1262-8
45. Nomoto A. Recombinant polioviruses as candidates for oral live poliovaccines. Microbiol Immunol 1993; 37: 169-74
46. Mattion NM, Reilly PA, DiMichele SJ, et al. Attenuated poliovirus strain as a live vector expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses. J Virol 1994; 68: 3925-33
47. Porter DC, Ansardi DC, Choi WS, et al. Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 gag and pol proteins upon infection. J Virol 1993; 67: 3712-9
48. Porter DC, Ansardi DC, Morrow CD. Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type I gag gene by using a complementation system which provides the P1 capsid protein in trans. J Virol 1995; 69: 1548-55
49. Moldoveanu Z, Porter DC, Lu A, et al. Immune responses induced by administration of encapsidated poliovirus replicons which express HIV-1 gag and envelope proteins. Vaccine 1995; 13: 1013-22
50. Conner ME, Matson DO, Estes MK. Rotavirus vaccines and vaccination potential. Curr Top Microbiol Immunol 1994; 185: 285-337
51. McNeal M, Broom RL, Ward RL. Active immunity against rotavirus infection in mice is correlated with viral replication and titers of serum rotavirus IgA following vaccination. Virology 1994; 204: 642-50
52. Offit PA, Coupar BEH, Svoboda YM, et al. Induction of rotavirus-specific cytotoxic T lymphocytes by vaccinia virus recombinants expressing individual rotavirus genes. Virology 1994; 198; 10-6
53. Offit PA, Khoury CA, Moser CA, et al. Enhancement of rotavirus immunogenicity by microencapsulation. Virology 1994; 203; 134-43
54. Feng N, Burns JW, Bracy L, et al. Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus. J Virol 1994; 68: 7766-73
55. National Institutes of Health, Division of Microbiology and Infectious Diseases. The Jordan Report: accelerated development for vaccines 1995. 13th ed. Bethesda (MD): National Institutes of Health, Division of Microbiology and Infectious Diseases, 1995: Appendix A
56. Kapikian AZ, Vesikari T, Ruuska T, et al. An update on the 'Jennerian' and modified 'Jennerian' approach to vaccination of infants and young children against rotavirus diarrhea. In: Ciardi JE, McGhee JR, Keith JM, editors. Genetically engineered vaccines. New York: Plenum Press, 1992: 59-69
57. Offil PA. Rotaviruses: immunological determinants of protection against infection and disease. Adv Virus Res 1994; 44: 161-202
58. Mestecky J, Abraham R, Ogra PL. Common mucosal immune system and strategies for the development of vaccines effective at the mucosal surface. In: Ogra PL, Mestecky J, Lamm ME, et al., editors. Handbook of mucosal immunology. San Diego: Academic Press, 1994: 357-72
59. Midthun K, Greenberg HB, Hoshino Y, et al. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 1985; 53: 949-54
60. Midthun K, Hoshino Y, Kapikian AZ, et al. Single gene substitution rotavirus reassortants containing the major neutralisation protein (VP7) of human rotavirus serotype 4. J Clin Microbiol 1986; 24: 822-6
61. Flores J, Perez-Schael I, Blanco M, et al. Reactogenicity and immunogenicity of a high-titer Rhesus rotavirus-based quadrivalent rotavirus vaccine. J Clin Microbiol 1993; 31: 2439-45
62. Perez-Schael I, Blanco M, Garcia D, et al. Evaluation of the antigenicity and reactogenicity of varying formulations of the Rhesus rotavirus-based quadrivalent and the M37 rotavirus vaccine candidates. J Med Virol 1994; 42: 330-7
63. Kobayashi M, Araki K, Thompson J, et al. Sequential administration of two human-Rhesus rotavirus reassortant strains of VP7 serotype 1 and 2 specificity to infants and young children. J Infect Dis 1993; 167: 748-52
64. Friedman MG, Segal B, Zedaka R, et al. Serum and salivary responses to oral tetravalent reassortant rotavirus vaccine in newborns. Clin Exp Immunol 1993; 92: 194-9
65. Pichichero ME, Marsocci SM, Francis AB, et al. A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral Rhesus rotavirus serotype 3, Rhesus/ human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants. Vaccine 1993; 11: 747-53
66. Bernstein DI, Glass RI, Rodgers G, et al. Evaluation of Rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995; 273: 1191-6
67. Centers for Disease Control. Summary - cases of specified notifiable diseases. United States. MMWR Morb Mortal Wkly Rep 1989; 37: 797
68. Conrad ME, Lemon SM. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis 1987; 156: 56-63
69. Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992; 14: 580-6
70. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-34
71. Westbloom TU, Gudipati S, DeRousse C, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule. J Infect Dis 1994; 169: 996-1001
72. Brindle RJ, Morris CA, Berger R, et al. Inadequate response to intradermal hepatitis A vaccine. Vaccine 1994; 12: 483-4
73. Green MS, Cohen D, Lerman Y, et al. A trial of the reactogenicity and immunogenicity of an inactivated hepatitis A vaccine. Isr J Med Sci 1994; 30: 485-8
74. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327: 453-7
75. Moyer L, Warwick M, Mahoney FJ. Prevention of hepatitis A virus infection. Am Fam Physician 1996; 54: 107-14
76. Levine MM, Ferreccio C, Black RE, et al. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11 Suppl. 3: 552-67
77. Dham SK, Thompson RA. Studies of cellular and humoral immunity in typhoid fever and TAB vaccinated subjects. Clin Exp Immunol 1982; 48: 389-95
78. Rajagopalan P, Kumar R, Malaviya AN. Astudy of humoral and cell mediated immune response following typhoid vaccination in human volunteers. Clin Exp Immunol 1982; 47: 275-82
79. Germanier R, Furer E. Isolation and characterization of galE mutant Ty21 a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J Infect Dis 1975; 131: 553-8
80. Roberts M, Chatfield SN, Dougan G. Salmonella as carriers of heterologous antigens. In: O'Hagan DT, editor. Novel delivery systems for oral vaccines. Boca Raton: CRC Press, 1994: 27-58
81. Kantele A. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine. J Biotechnol 1996; 44: 217-24
82. Nisini R, Biselli R, Matricardi PM, et al. Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. Vaccine 1993; 11: 582-6
83. Bellanti JA, Zeligs BJ, Vetro S, et al. Studies of safety, infectivity and immunogenicity of a new temperature-sensitive (ts) 51-1 strain of Salmonella typhi as a new live oral typhoid fever vaccine candidate. Vaccine 1993; 11: 587-90
84. Hone DM, Harris AM, Chatfield S, et al. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 1991; 9: 810-6
85. Chatfield SN, Fairweather N, Charles I, et al. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine 1992; 10: 53-60
86. Tacket CO, Hone DM, Losonsky GA, et al. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 1992; 10: 443-6
87. Tackett CO, Hone DM, Curtiss III R, et al. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi strains in adult volunteers. Infect Immun 1992; 60: 536-41
88. Black RE, Levine MM, Clements ML, et al. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun 1987; 55: 1116-20
89. Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature 1981; 292: 413-7
90. Svennerholm AM, Jerthorn M, Gothefors L, et al. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with B subunit-whole cell vaccine. J Infect Dis 1984; 149: 884-93
91. Holmgren J, Svennerholm AM, Lönnroth I, et al. Development of improved cholera vaccine based on subunit toxoid. Nature 1977; 269: 602-4
92. Svennerholm AM, Holmgren J. Synergistic protective effect in rabbits of immunization with Vibrio cholerea lipopolysaccharide and toxin/toxoid. Infect Immun 1976; 13: 735-40
93. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; 11: 124-7
94. Holmgren J, Svennerholm AM, Jertborn M, et al. An oral B subunit: whole cell vaccine against cholera. Vaccine 1992; 10: 911-4
95. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic. Escherichia coli: results of a large-scale field trial. J Infect Dis 1988; 158: 372-7
96. Quiding M, Nordström I, Kilander A, et al. Intestinal immune responses in humans: oral cholera vaccination induces strong intestinal antibody responses and interferon-γ production and evoked local immunological memory. J Clin Invest 1991; 88: 143-8
97. Mekalanos JJ, Sadoff JC. Cholera vaccines: fighting an ancient scourge. Science 1994; 265: 1387-9
98. Kotloff KL, Wasserman SS, O'Donnell S, et al. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial. Infect Immun 1992; 60: 4430-2
99. Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992; 166: 837-41
100. Cryz SJ, Que JU, Levine MM, et al. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults. Infect Immun 1995; 63: 1336-9
101. Lagos R, Avendaño A, Prado V, et al. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun 1995; 63: 707-9
102. Simanjuntak CH, O'Hanley P, Punjabi NH, et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis 1993; 68: 1169-76
103. Taylor DN, Killee KP, Hack DC, et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 1994; 170: 1518-23
104. Albert MJ, Siddique AK, Islam MS, et al. Large outbreak of clinical cholera due to Vibrio cholerae non-01 in Bangladesh [letter]. Lancet 1993; 341: 704
105. Ramamurthy T, Garg S, Sharma R, et al. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India [letter]. Lancet 1993; 341: 703-4
106. Waldor MK, Mekalanos JJ. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae 0139 and development of a live vaccine prototype. J Infect Dis 1994; 170: 278-83
107. Coster TS, Killeen KP, Waldor MK, et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae 0139 vaccine prototype. Lancet 1995; 345: 949-52
108. Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine 1993; 11: 207-12
109. Mallet CP, Van De Verg L, Collins HH, et al. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 1993: 11: 190-6
110. Taylor DN, Phillip DF, Zapor M, et al. Outpatient studies of the safety and immunogenicity of an auxotrophic Escherichia coli K-12-Shigella flexneri 2a hybrid vaccine candidate. EcSf2a-2. Vaccine 1994; 12: 565-8
111. Noriega FR, Wang JY, Losonsky G, et al. Construction and characterization of attenuated Δaro ΔvirG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun 1994; 62: 5168-72
112. Telford JL, Covacci A, Ghiara P, et al. Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential new therapies and vaccines. Trends Biotechnol 1994; 12: 420-6
113. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19 Suppl. 1: 37-43
114. Kenneny MB. Helicobacter pylori. Arch Intern Med 1994; 154: 721-7
115. Czinn SJ, Nedrud JG. Oral immunization against Helicobacter pylori. Infect Immun 1991; 59: 2359-63
116. Lee A, Chen M. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole cell vaccine. Infect Immun 1994; 62: 3594-7
117. Buck FJ, Doidge C, Lee A. Therapeutic immunisation: the future for Helicobacter treatment [abstract]. In: Kagnoff MF, Kiyono H, Rose NR, et al., editors. Clinical Immunology and Immunopathology, 8th International Congress of Mucosal Immunology: 1995 Jul 17-20. San Diego: Academic Press, 1995: 39
118. Thiberge JM, Kansau I, Wuscher N, et al. Immunization with H. pylori heat-shock and urease subunit proteins affords total protection against Helicobacter infection in mice [abstract]. In: Kagnoff MF, Kiyono H, Rose NR, et al., editors. Clinical Immunology and Immunopathology, 8th International Congress of Mucosal Immunology: 1995 Jul 17-20, San Diego: Academic Press, 1995: 40
119. Monath TP, Kleanthous H, Thomas WD, et al. Recombinant urease apoenzyme as an oral prophylactic and therapeutic vaccine against Helicobacter pylori [abstract]. In: Kagnoff MF, Kiyono H, Rose NR, et al., editors. Clinical Immunology and Immunopathology, 8th International Congress of Mucosal Immunology: 1995 Jul 17-20. San Diego: Academic Press, 1995: 45
120. Marchetti M, Arico B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995; 267: 1655-8
121. Guerray P, Pope PM, Burr DH, et al. Development and characterization of recA mutants of Campylobacter jejuni for inclusion in attenuated vaccines. Infect Immun 1994; 62: 426-32
122. Rollwagen FM, Pacheco ND, Clements JD, et al. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine 1993; 11: 1316-20
123. Elson CO, Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 1984; 133: 2892-7
124. Pizza M, Fontana MR, Giuliani MM, et al. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J Exp Med 1994; 180: 2147-53
125. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Ogra PL, Mestecky J, Lamm ME, et al., editors. Handbook of mucosal immunology. San Diego: Academic Press, 1994: 391-402
126. Nashar TO, Amin T, Marcello A, et al. Current progress in the development of B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine 1993; 11: 235-40
127. Ramsay AJ, Kohonen-Corish M. Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo. Eur J Immunol 1993; 23: 3141-5
128. Bromander AK, Ekman L, Kohler G, et al. Mucosal IgA responses are not impaired in IL-6 knockout mice (abstract). In: Kagnoff MF, Kiyono H, Rose NR, et al., editors. Clinical Immunology and Immunopathology, 8th International Congress of Mucosal Immunology: 1995 Jul 17-20. San Diego: Academic Press, 1995: 30
129. Leong KH, Ramsay AJ, Boyle DB, et al. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol 1994; 68: 8125-30
130. Baqar S, Pacheco ND, Rollwagen FM. Modulation of mucosal immunity against Campylobacter jejuni by orally administered cytokines. Antimicrob Agents Chemother 1993; 37: 2688-92
131. Maloy KJ, Donachie AM, O'Hagan DT, et al. Induction of mucosal and systemic immune responses by immunisation with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994; 81: 661-7
132. Jackson RJ, Staats HF, Xu-Amano J, et al. Oral vaccine models: multiple delivery systems employing tetanus toxoid. Ann NY Acad Sci 1994; 730: 217-34
133. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 1990; 11: 89-97
134. Manesis EK, Cameron CH, Gregoriadis G. Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen. FEBS Lett 1979; 102: 107-11
135. Alving CR. Lipopolysaccharide, lipid A and liposomes containing lipid A as immunologic adjuvants. Immunobiology 1993; 187: 430-46
136. Johnson AG, Tomai M, Solem L, et al. Characterization of a non-toxic monophosphoryl lipid A. Rev Infecl Dis 1987; 9 Suppl. 5: 512-6
137. Takayama K, Olsen M, Datta P, et al. Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors. Vaccine 1991; 9: 257-65
138. van de Wijgert JHHM, Verheul AFM, Snippe H, et al. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution. Infect Immun 1991; 59: 2750-7
139. Myers KR, Beining P, Betts M, et al. Monophosphoryl lipid A behaves as a T cell-independent type 1 carrier for hapten-specific antibody responses in mice. Infect Immun 1995; 63: 168-74
140. Pierce NF, Sacci Jr JB, Alving CR, et al. Enhancement by lipid A of mucosal immunogenicity of liposome-associated cholera toxin. Rev Infect Dis 1984; 6: 563-6
141. Morein B, Sundquist B, Hoglund S, et al. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308: 457-60
142. Claassen I, Osterhaus A. The iscom structure as an immune-enhancing moiety: experience with viral systems. Res Immunol 1992; 143: 531-41
143. Lehner T, Brookes R, Pnagiotidi C, et al. T and B cell function and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route. Proc Natl Acad Sci USA 1993; 90: 8638-42
144. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 1995; 3: 165-9
145. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9
146. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478-82
147. Size-more DR, Branstorm AA, Sadoft JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995; 270: 299-302
148. Mason HS, Lam DMK, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA 1992; 89: 11745-9
149. Thanavala Y, Yang YF, Lyons P, et al. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci USA 1995; 92: 3358-61
150. Haq TA, Mason HS, Clemens JD, et al. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995; 268: 714-6
151. Ma JCK, Hiatt A, Hein M, et al. Generation and assembly of secretory antibodies in plants. Science 1995; 268: 716-9